IOLCP · NSE
IOL Chemicals and Pharmaceuticals Limited
₹203.15
+2.87% (+₹5.66)
Prev. close
₹197.49
Volume
46,95,376
Delivery %
33.5%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited manufactures and sells pharmaceutical and chemical products in India and internationally. It operates through two segments: Pharmaceuticals and Specialty Chemicals. The Chemical segment offers ethyl acetate, iso butyl benzene, acetyl chloride, mono chloro acetic acid, and acetic anhydride to the food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, plasticizers and ploymers, and chemical intermediates industries. The Pharmaceutical segment provides active pharmaceutical ingredients, such as ibuprofen, metformin, fenofibrate, lamotrigine, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, gabapentin, levetiracetam, and paracetamol. Its active pharmaceutical ingredients are used for the treatment of anti-inflammatory, analgesic and antipyretic, anti-diabetic, antiplatelet, anti-cholesterol, anti-convulsant, anti-epileptic, anti-hypertensive, and anti-cholelithic, as well as proton pump inhibitor. IOL Chemicals and Pharmaceuticals Limited was incorporated in 1986 and is based in Ludhiana, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Varinder Gupta
Headquarters
Ludhiana
Employees
3,095
Website
iolcp.comExchange
View on NSE ↗Key stats
Market cap
₹5,963.01 Cr
P/E ratio (TTM)
35.5
Dividend yield
0.51%
EPS (TTM)
₹5.73
Beta (1Y · daily vs NIFTY 50)
1.22
Beta (5Y · monthly vs NIFTY 50)
1.21
Shares float
8.25 Cr
EPS · quarter ended Jun 2026
₹2.19
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,966.98 Cr | ₹2,184.02 Cr | ₹2,217.11 Cr | ₹2,132.79 Cr | ₹2,079.21 Cr | ₹2,319.06 Cr | |
| EBITDA | ₹616.14 Cr | ₹276.40 Cr | ₹251.28 Cr | ₹260.66 Cr | ₹224.71 Cr | ₹279.14 Cr |
| ₹444.56 Cr | ₹167.67 Cr | ₹139.14 Cr | ₹134.43 Cr | ₹101.07 Cr | ₹137.64 Cr | |
| Diluted EPS | ₹15.24 | ₹5.71 | ₹4.74 | ₹4.58 | ₹3.44 | ₹4.69 |
EBITDA for Mar 2022 could not be independently verified against the company's own annual report: this page shows ₹276.40 Cr while the annual report gives ₹290.33 Cr (5.0% apart).
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹1,962.00 Cr | ₹2,022.00 Cr | ₹2,244.00 Cr | ₹2,382.00 Cr | ₹2,587.00 Cr | |
| — | — | ₹79.81 Cr | ₹32.76 Cr | ₹117.04 Cr | ₹135.42 Cr | |
| Stockholders' equity | — | ₹1,393.00 Cr | ₹1,508.00 Cr | ₹1,612.00 Cr | ₹1,688.00 Cr | ₹1,799.00 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹379.78 Cr | ₹93.00 Cr | ₹122.00 Cr | ₹290.00 Cr | ₹179.00 Cr | ₹214.00 Cr | |
| Investing cash flow | ₹-317.25 Cr | ₹-120.19 Cr | ₹-120.00 Cr | ₹-191.28 Cr | ₹-154.18 Cr | ₹-198.11 Cr |
| ₹-58.28 Cr | ₹-1.64 Cr | ₹-4.11 Cr | ₹-92.50 Cr | ₹46.04 Cr | ₹-29.03 Cr | |
| Capital expenditure | ₹-109.43 Cr | ₹-154.43 Cr | ₹-211.82 Cr | ₹-274.71 Cr | ₹-213.55 Cr | ₹-172.99 Cr |
| End cash position | ₹32.34 Cr | ₹3.56 Cr | ₹1.39 Cr | ₹7.69 Cr | ₹78.17 Cr | ₹65.35 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22–Dec 22(4Q) | Mar 23–Sep 24(7Q) | Dec 24–Dec 25(5Q) | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|
| Promoter | 43.69% | 43.69% | 43.69% | 48.19% | 52.62% | 57.48% | 62.28% |
| Public | 56.31% | 56.30% | 56.31% | 51.81% | 47.38% | 42.52% | 37.72% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| IOL Chemicals and Pharmaceuticals Limited | ₹5,723.79 Cr | ₹194.31 | 34.2 | 3.18 | 7.7% | 0.08 | +11.6% | +62.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 24
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
IOL Chemicals IOLCP: Ibuprofen Expansion and CDMO Plans
IOL Chemicals and Pharmaceuticals announced three expansion initiatives funded by internal accruals. The company will increase Ibuprofen manufacturing capacity by 50% to 18,000 MTPA and establish a new CDMO pharmaceutical formulations facility. Additionally, a dedicated specialty chemicals facility is being set up under a long-term tolling arrangement.